Table 2 Prevalence rates of MPS in various countries per 100,000 live births
Prevalence per 100,000 live births | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Country Study period | Japan 1982–2009 | Switzerland 1982–2009 | United States 1995–2005 | Poland 1970–2010 | Brazil 1994–2018 | The Netherlands 1970–1996 | Australia 1980–1996 | Northern Portugal 1982–2001 | Czech Republic 1975–2008 | Sweden 1975–2004 | Denmark 1975–2004 | Norway 1979–2004 |
References | Khan et al., 2017 [137] | Puckett et al., 2021 [21] | Jurecka et al., 2014 [138] | Josahkian et al., 2021 [139] | Poorthuis et al., 1999 [22] | Meikle et al., 1999 [1] | Pinto et al., 2004 [140] | Poupetová et al., 2010 [141] | Malm et al., 2008 [142] | |||
MPS I | 0.23 | 0.19 | 0.0007 | 0.22 | 0.29 | 1.19 | 1.14 | ─ | 0.72 | 0.67 | 0.54 | 1.85 |
Hurler | 1.05 | ─ | ||||||||||
Hurler/Scheie | 1.33 | ─ | ||||||||||
Scheie | 0.28 | ─ | ||||||||||
MPS II | 0.84 | 0.46 | 0.0007 | 0.46 | 0.48 | 0.67 | 0.74 | 1.09 | 0.43 | 0.27 | 0.27 | 0.13 |
MPS III | 0.26 | 0.38 | 0.00071 | 0.86 | ─ | 1.89 | 1.51 | 0.84 | 0.91 | 0.67 | 0.43 | 0.27 |
IIIA | ─ | ─ | 0.00052 | ─ | 0.08 | 1.16 | ─ | 0 | 0.47 | ─ | ─ | ─ |
IIIB | ─ | ─ | 0.00014 | ─ | 0.12 | 0.42 | ─ | 0.72 | 0.02 | ─ | ─ | ─ |
IIIC | ─ | ─ | 0.00004 | ─ | 0.07 | 0.21 | ─ | 0.12 | 0.42 | ─ | ─ | ─ |
IIID | ─ | ─ | 0 | ─ | 0.001 | 0.1 | ─ | ─ | 0 | ─ | ─ | ─ |
MPS IV | 0.15 | 0.38 | 0.00038 | 0.14 | ─ | ─ | 0.59 | ─ | 0.73 | 0.07 | 0.48 | 0.76 |
IVA | ─ | ─ | 0.00029 | ─ | 0.15 | 0.22 | ─ | 0.6 | 0.71 | ─ | ─ | ─ |
IVB | ─ | ─ | 0.00001 | ─ | 0.003 | 0.14 | ─ | ─ | 0.02 | ─ | ─ | ─ |
MPS VI | 0.03 | 0.11 | 0.00011 | 0.0132 | 0.35 | 0.15 | 0.43 | 0.42 | 0.05 | 0.07 | 0.05 | 0.07 |
MPS VII | 0.02 | 0.038 | 0.00007 | 0 | 0.02 | 0.24 | 0.047 | 0 | 0.02 | ─ | ─ | ─ |
MPS IX | ─ | ─ | 0 | 0 | 0 | ─ | ─ | ─ | ─ | ─ | ─ | ─ |
MPS X | ─ | |||||||||||